{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"63","value":"14.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"MEDIAN","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"From first dose of study drug through the end of follow-up; median (minimum, maximum) time on study was 33.8 (1, 62) months.","title":"Resource Utilization: Duration of Hospitalization","type":"SECONDARY","unitOfMeasure":"days"}